Upstream Bio Inc (UPB)

Mar 1, 2026, 9:45 AM EST - 20 days ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Feb 26, 2026, 7:00 AM EST - 23 days ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 25, 2026, 7:00 AM EST - 24 days ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 13, 2026, 10:45 AM EST - 5 weeks ago

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Feb 11, 2026, 9:02 AM EST - 5 weeks ago

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Feb 11, 2026, 6:00 AM EST - 5 weeks ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 10, 2026, 6:00 PM EST - 5 weeks ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Jan 5, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 4:48 PM EST - 3 months ago

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Nov 25, 2025, 7:00 AM EST - 4 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 5, 2025, 7:00 AM EST - 4 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Oct 31, 2025, 7:00 AM EDT - 5 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Sep 30, 2025, 4:15 AM EDT - 6 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 9, 2025, 7:00 AM EDT - 6 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 7, 2025, 10:25 PM EDT - 6 months ago

Upstream Bio, Inc. - Special Call

Sep 2, 2025, 6:00 AM EDT - 7 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 7 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jun 15, 2025, 7:45 AM EDT - 9 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 5, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 6, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Apr 17, 2025, 5:51 PM EDT - 1 year ago

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Mar 28, 2025, 3:56 PM EDT - 1 year ago

3 Dividend Giants To Buy As Tariffs Hit Stocks

PEP PG

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Dec 16, 2024, 1:03 PM EST - 1 year ago

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Nov 5, 2024, 3:09 PM EST - 1 year ago

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering